<DOC>
	<DOCNO>NCT02417246</DOCNO>
	<brief_summary>Recently , quality generic metoprolol extended-release ( ER ) ( Toprol XL , Activas , Wockhardt ) product call question report inconsistent effect switch brand name product generic formulation . Problems body process drug could serious widespread consequence give high frequency metoprolol ER use management various cardiovascular disorder , include high blood pressure , coronary heart disease , heart failure , cardiac arrhythmia . Investigators hypothesize product- subject-specific factor lead variability way body breaks drug ( pharmacokinetics ) clinical response generic versus name brand metoprolol ER formulation . Investigators study brand name generic metoprolol ER formulation subject high blood pressure compare pharmacokinetics cardiovascular response among equivalent label dos product . The study objective provide information body break generic brand name metoprolol ER product ( pharmacokinetics ) body respond generic brand name metoprolol ER product ( pharmacodynamics ) good understand generic metoprolol ER product good brand name product .</brief_summary>
	<brief_title>Open-Labeled PK-PD Studies Metoprolol ER</brief_title>
	<detailed_description>As participant study follow happen . A study nurse draw 3 teaspoonful ( 15 ml ) blood . Two teaspoon ( 10ml ) drawn basic blood work one teaspoon ( 5ml ) drawn genotyping . The study physician , Dr. Sigfried Schmidt perform physical exam discus medical history . The study randomize one two group like flip coin . - Study Group A- start Toprol XL , switch Wockhardt metoprolol , switch back Toprol XL , switch Activas metoprolol - Study Group B- start Toprol XL , switch Activas metoprolol , switch back Toprol XL , switch Wockhardt metoprolol . Each study group consist treatment Toprol XL 2 period , treatment Wockhardt metoprolol one period , treatment Activas metoprolol one period . The generic drug period different order study group . During time switch take place follow test perform : 24-hour pharmacokinetic parameter , 24-hour heart rate , 24-hour blood pressure , 24-hour holter monitor , exercise treadmill induce heart rate , 24-hour gastric pH SmartPill Capsule .</detailed_description>
	<mesh_term>Metoprolol</mesh_term>
	<criteria>Subjects target enrollment base current treatment hypertension betablocker know tolerability betablocker base previous participation Pharmacogenomic Evaluation Antihypertensive Responses study ( PEAR1 PEAR2 ) . If necessary meet enrollment target , additional patient recruit exist patient population UF Health Family Medicine clinic Documented secondary form HTN Known cardiovascular disease ( include history angina pectoris , myocardial infarction , coronary revascularization procedure , heart failure , presence cardiac pacemaker ) Known cerebrovascular disease ( include stroke TIA ) Known peripheral vascular disease Diabetes mellitus ( Type 1 2 ) ( define diabetes diagnosis medical record fasting blood glucose great equal 126 mg per dl nonfasting blood glucose great equal 200 mg per dl screen laboratory ) Systolic blood pressure ( SBP ) great than180 mm Hg screen visit Heart rate le 55 bpm screen visit ( absence treatment betablocker ) Renal insufficiency ( serum creatinine great 1.5 men great 1.4 woman screen laboratory ) Liver enzyme ( ALT AST ) great 3 time upper limit normal screen laboratory . Known Raynaud 's phenomenon Known asthma chronic obstructive pulmonary disease Pregnancy lactation Gastric bezoar Swallowing disorder Strictures Fistulas GI obstruction Severe dysphagia Crohn 's disease Diverticulitis Any implantable electromedical device Use nondihydropyridine calcium channel blocker ( diltiazem verapamil ) Use digoxin avoid additive effect heart rate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>pharmacogenetics</keyword>
</DOC>